Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease

Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets

(2020) Somin Kwon et al.   Neurotherapeutics

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

(2019) Francesco Panza et al.   Nature Reviews Neurology

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease

(2019) Bernard J. Hanseeuw et al.   JAMA Neurology

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

A resurrection of aducanumab for Alzheimer's disease

(2019) Lon Schneider   LANCET NEUROLOGY

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

(2018) Christopher H. van Dyck   BIOLOGICAL PSYCHIATRY

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model

(2018) Hugo Geerts et al.   Alzheimers Research & Therapy

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis

(2017) Jia-Jie Mo et al.   Annals of Clinical and Translational Neurology

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer’s Disease: Need for Prognostic Biomarkers?

(2016) Fabrizio Piazza et al.   JOURNAL OF ALZHEIMERS DISEASE

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

(2016) Ross Penninkilampi et al.   Journal of Neuroimmune Pharmacology

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

(2016) Rik Vandenberghe et al.   Alzheimers Research & Therapy

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy

(2015) Jacopo C. DiFrancesco et al.   Frontiers in Neurology

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

What is the clinically relevant change on the ADAS-Cog?

(2011) Anette Schrag et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE